Harmony Biosciences Holdings, Inc

Section 1: Company Overview and Fundamentals

1.1 Company Overview:

Harmony Biosciences Holdings, Inc (NASDAQ: HRMY) is a biopharmaceutical company dedicated to advancing and marketing treatments for individuals with rare neurological disorders and other neurological conditions with significant unmet needs. Its lead therapy, WAKIX (pitolisant), is a first-in-class drug that works through a unique mechanism of action by targeting H3 receptors to enhance histamine activity in the brain.

Kalkine’s Diversified Opportunities Report covers the Company Overview, Key positives & negatives, Investment summary, Key investment metrics, Top 10 shareholding, Business updates and insights into company recent financial results, Key Risks & Outlook, Price performance and technical summary, Target Price, and Recommendation on the stock.

Stock Performance:

• The stock peaked in Jan 2025 above USD 40 but faced a sharp correction, bottoming near USD 30 in April 2025. Since then, it has staged a recovery, forming higher lows and regaining momentum above both the 21-day and 50-day moving averages, showing a shift to a more constructive trend.
• The 21-day MA (USD 36.53) is above the 50-day MA (USD 35.29), indicating a short-term bullish crossover that supports positive momentum. Price is holding slightly above both averages, confirming a potential bullish movement.
• The RSI at 54 reflects a neutral stance, neither overbought nor oversold. This indicates the stock is consolidating with room for movement in either direction.

1.2 The Key Positives, Negatives, and Investment summary

1.3 Top 10 shareholders:

The top 10 shareholders together form ~ 54.18% of the total shareholding, signifying concentrated shareholding. Marshman Fund Trust ii and BlackRock Institutional Trust Company, N.A. are the biggest shareholders, holding the maximum stake in the company at 10.52% and 10.03%, respectively.

1.4 Key Metrics:

The chart highlights Harmony Biosciences’ strong cash generation in late FY2024, as operating cash flow rose sharply from USD 73.8 million in Q2 FY2024 to USD 219.8 million in Q4 FY2024, driven by WAKIX® revenue growth and profitability, which lifted FCF yield to 21.9%. In Q1 FY2025, FCF yield fell to 3.2% as operating cash flow dropped to USD 34.0 million, reflecting timing of expenses, higher administrative costs, and investment-related outflows. By Q2 FY2025, FCF yield recovered to 10.2% as operating cash flow improved to USD 113.3 million, supported by 16% YoY revenue growth, higher net income, and reduced R&D charges, despite total assets rising to USD 1,108 million.

Section 2: Business Updates and Corporate Business Highlights

2.1 Recent Business Updates

2.2 Insights of Q2FY25:

Section 3: Key Risks & Outlook

Section 4: Stock Recommendation Summary:

4.1 Price Performance and Technical Summary:

Stock Performance:

• The stock peaked in Jan 2025 above USD 40 but faced a sharp correction, bottoming near USD 30 in April 2025. Since then, it has staged a recovery, forming higher lows and regaining momentum above both the 21-day and 50-day moving averages, showing a shift to a more constructive trend.
• The 21-day MA (USD 36.53) is above the 50-day MA (USD 35.29), indicating a short-term bullish crossover that supports positive momentum. Price is holding slightly above both averages, confirming a potential bullish movement.
• The RSI at 54 reflects a neutral stance, neither overbought nor oversold. This indicates the stock is consolidating with room for movement in either direction.

 4.2 Fundamental Valuation

Valuation Methodology: Price/Earnings per share Multiple Based Relative Valuation

Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is September 04, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: The report publishing date is as per the Pacific Time Zone.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

 Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.

 Stop-loss: It is a level to protect against further losses in case of unfavorable movement in the stock prices.